Oncology Corporate Profile
Leap Therapeutics was founded on the principle that investing in great science and targeted research will rapidly translate molecules into high impact therapeutics. Our pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology. Led by a proven management team, Leap Therapeutics is dedicated to building and developing a pipeline of therapeutics that has the potential to change the practice of cancer medicine.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|DKN-01||anti-DKK1 antibody||Esophageal cancer||I|
|DKN-01||anti-DKK1 antibody||Non Small Cell Lung Cancer (NSCLC)||I|
|TRX518||anti-GITR antibody||Various cancer types||I|
|DKN-01 (+ pembrolizumab)||anti-DKK1 antibody||Esophageal cancer||Preclinical||Merck|